Mocetinostat (MGCD0103)

For research use only. Not for use in humans.

目录号:S1122 别名: MG0103

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) 是一种有效的HDAC抑制剂,对HDAC1抑制作用最强,无细胞试验中IC50为0.15 μM,比作用于HDAC2, 3,和11选择性高2到10倍,对HDAC4, 5, 6, 7,和8没有抑制活性。Mocetinostat (MGCD0103) 可诱导凋亡和自噬。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1563.11 现货
RMB 1382.65 现货
RMB 2233.39 现货
RMB 3862.98 现货
RMB 6314.53 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Mocetinostat (MGCD0103)发表文献76篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Mocetinostat (MGCD0103, MG0103) 是一种有效的HDAC抑制剂,对HDAC1抑制作用最强,无细胞试验中IC50为0.15 μM,比作用于HDAC2, 3,和11选择性高2到10倍,对HDAC4, 5, 6, 7,和8没有抑制活性。Mocetinostat (MGCD0103) 可诱导凋亡和自噬。Phase 2。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
0.15 μM 0.29 μM 0.59 μM 1.66 μM
体外研究

MGCD0103按剂量依赖性在纳摩尔浓度或低微摩尔浓度时只能抑制9个人类重组HDACs中的一部分,包括HDAC1, HDAC2, HDAC3, 和HDAC11。在体外,MGCD0103有效抑制人类HDAC1和HDAC2酶,但是不抑制二级HDACs。MGCD0103的外环氨基抑制酶时是必需的,因为作用于HDAC1和HDAC2的HDAC抑制活性已被desamino类似物全部消除。MGCD0103 6 μM时抑制活性达到最高状态,在HCT116细胞中MGCD0103最高抑制全部酶活的75%,而NVP-LAQ824抑制几乎达到100%。MGCD0103抑制A549细胞时也显示出剂量依赖性。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j3PFQ5KGh? M4fpXGlEPTB;Mz6wOEDPxE1? M{[4XVI3Ozd6MEO4
BT549 NX7jRYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDzfG41QCCq NV;leFl3UUN3ME20MlM5KM7:TR?= MXeyOlM4QDB|OB?=
MCF7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XuNFQ5KGh? MYDJR|UxRTBwNkeg{txO NXzMc5EzOjZ|N{iwN|g>
T47D NGLEVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWi0PEBp MnzlTWM2OD1zLkG3JO69VQ>? NIT2OZMzPjN5OECzPC=>
MOLP8 NYToenk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TFZ|Q5KGh? M4fM[mlEPTB;MD62xtEhOC5yNN88US=> M{nM[lI3ODlzNUG4
Panc1 MlfrSpVv[3Srb36gRZN{[Xl? NFnrT2QxNjVxMT:yMlUh|ryP M4juZ|Q5KGh? MlvTSG1UVw>? NXz1Zlh1fXC{ZXf1cIF1\XNibXnSMVIxOw>? M3fSc|I2QDd{OUSx
Panc1 M3PBeGZ2dmO2aX;uJGF{e2G7 MXmwMlUwOS9{LkWg{txO M2PlXVQ5KGh? MlnVSG1UVw>? MVHy[YR2[2W|IHX4dJJme3Orb36gc4YhYkWEMTDvckBjd3SqIH3SUmEh[W6mIIDyc5RmcW5ibHX2[YzDqA>? M{fQclI2QDd{OUSx
Panc1 MU\BdI9xfG:|aYOgRZN{[Xl? NUD3UWtKOcLizszN M2fyNVczyqCq M3TsbWROW09? Mo\Ld4Vve2m2aYrld{BR[W6lMTDj[YxteyCob4Kg[4Vu[2m2YXLpcoUucW6mdXPl[EBieG:ydH;zbZM> NHzUS4szPTh5Mkm0NS=>
Panc1 NEjES|ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF[zW|AyyqEQvF2= M{Tz[FczyqCq MXfEUXNQ NWTxWIp[\W6qYX7j[ZMh\2WvY3n0ZYJqdmVvaX7keYNmeyClZXzsJJZq[WKrbHn0fUBl\WO{ZXHz[S=> NFLz[48zPTh5Mkm0NS=>
MMCs NWq2dWpYTnWwY4Tpc44hSXO|YYm= NULlWoJ1OSEQvH2= M{LL[VAuPDhiaB?= MmnkbY5kemWjc3XzJG5RWkFicILveIVqdiCneIDy[ZN{cW:wwrCyMlfjiJN|LkWg[o9t\A>? MVyyOFQ2OTN5OB?=
MMCs MUDGeY5kfGmxbjDBd5NigQ>? MUmwMlUwOSEQvF2= MYiyOEBp NW\WW|Q4e2ixd4OgOFUu\m:uZDDzeIlufWyjdHnvckBqdiClR13QJIxmfmWucx?= MUWyOFQ2OTN5OB?=
MMCs Mkm4SpVv[3Srb36gRZN{[Xl? MXyxxsDPxE1? MlvzNlQhcA>? NF35RZJqdmO{ZXHz[ZMhUEGWIHHjeIl3cXS7 NF7Vc3gzPDR3MUO3PC=>
MMCs NE\IcYNHfW6ldHnvckBCe3OjeR?= MVKxxsDPxE1? MYOyOEBp M{HZN4F2\22nboTzJIdtd2KjbDDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhcGm|dH;u[UBJOy2NOT:xOEApUDNvS{mvNVRi[yliYX7kJGg1NUtzMjCoTFQuUzF{YXOp NXO5eGl{OjR2NUGzO|g>
MMCs M{DY[WZ2dmO2aX;uJGF{e2G7 NVLPNHJ3OcLizszN NV3KfVc3Pi1{NDDo NFqxdGlld3OnLXTldIVv\GWwdHz5JIlvcGmkaYTzJJRp\SC2cnnt[ZRpgWyjdHnvckBt\X[nbDDv[kBJOy2NOTCoTFMuUzmvZUOp MlfyNlQ1PTF|N{i=
BxPC-3 NFjuO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm3SWM2OD1zLkGg{txO MX:yNVM4PTZ5OR?=
AsPC-1 NFnuZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzR[Wc6TUN3ME2zMlkh|ryP MVSyNVM4PTZ5OR?=
MiaPaca-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\wO21GSzVyPUCuOkDPxE1? NVTqXI9{OjF|N{W2O|k>
Panc-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHPRpBWTUN3ME2xMlgh|ryP MYOyNVM4PTZ5OR?=
PAXF 546L† MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Qb2VEPTB;MT61JO69VQ>? NHW0dYIzOTN5NU[3PS=>
PAXF 1657L† MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTFR|UxRTBwMzFOwG0> NXm4fpg5OjF|N{W2O|k>
HCT15 NV7pUmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNSZhqUUN3ME2wMlch|ryP MmLDNlE{OTd2NUW=
HT-29 MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNzFOwG0> M2TY[FIyOzF5NEW1
SW48 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LhV2lEPTB;MD64JO69VQ>? MV[yNVMyPzR3NR?=
SW620 M{TaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP0TWM2OD1zIN88US=> M4X0OlIyOzF5NEW1
HMEC NHPh[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\kW41KSzVyPUG5JO69VQ>? NH76PGszOTNzN{S1OS=>
ANBL6  MoHYSpVv[3Srb36gRZN{[Xl? NYHwVm1XOcLizszN NIHscXYzPCCq M3XBd4VvcGGwY3XzJFUuSUNvaX7keYNm\CCPQVfFMWE{KGenbnWg[ZhxemW|c3nvci=> NIjBbWYzOTF5MUiyNS=>
LP1 M4LidmZ2dmO2aX;uJGF{e2G7 M4HxVlHDqM7:TR?= MYiyOEBp NHnUfnlmdmijbnPld{A2NUGFLXnu[JVk\WRiTVHHSU1COyCpZX7lJIV5eHKnc4Ppc44> NW\KPIpLOjFzN{G4NlE>
HD-LM2 NVfHXYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NuKhcA>? NUXiXpFWTE2VTx?= MVXJR|UxRTFwOEig{txO MWGyNFg5ODFyNx?=
L428 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PXfFczyqCq MYrEUXNQ MV;JR|UxRTFwOU[g{txO NEHsXoQzODh6MEGwOy=>
KM-H2 MofNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTydIdDPzMEoHi= M{TM[GROW09? NGq0RXdKSzVyPUKuPFYh|ryP MVmyNFg5ODFyNx?=
HD-LM2 NXTRZ29nTnWwY4Tpc44hSXO|YYm= MnzxNE4yNTJizszN M2r2cVI1KGkEoB?= Mn6xSG1UVw>? MXvzbI94eyCjY3X0fYxifGmxbjDv[kBpcXO2b37lJFMh[W6mIIXwdoVofWyjdHnvckBw\iC2aHWgZ4VtdCCleXPs[UBz\We3bHH0c5J6KHC{b4TlbY4heDJz Mke3NlA5QDBzMEe=
L428 MmfHSpVv[3Srb36gRZN{[Xl? Mm\mNE4yNTJizszN NEnCb|UzPCCqwrC= MnfFSG1UVw>? MUnzbI94eyCjY3X0fYxifGmxbjDv[kBpcXO2b37lJFMh[W6mIIXwdoVofWyjdHnvckBw\iC2aHWgZ4VtdCCleXPs[UBz\We3bHH0c5J6KHC{b4TlbY4heDJz M370WlIxQDhyMUC3
KM-H2 M3rMXGZ2dmO2aX;uJGF{e2G7 MonQNE4yNTJizszN MUSyOEBpyqB? MX3EUXNQ M4L2VJNpd3e|IHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhOyCjbnSgeZBz\We3bHH0bY9vKG:oIITo[UBk\WyuIHP5Z4xmKHKnZ4XsZZRwenlicILveIVqdiCyMkG= M{nVd|IxQDhyMUC3
HD-LM2 M2fuWWFxd3C2b4Ppd{BCe3OjeR?= M2e0UlAvOS9yLkWvNUDPxE1? M1HqOFQ5KGh? NF;FWpdFVVOR M4r4W4lv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NYDOVlRWOjB6OECxNFc>
L428 NV2xeFAxSXCxcITvd4l{KEG|c3H5 NU\GemVFOC5zL{CuOU8yKM7:TR?= M3nQNFQ5KGh? NF;jSlVFVVOR NH\CNXhqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 Mo\ONlA5QDBzMEe=
KM-H2 NVTMTZJ{SXCxcITvd4l{KEG|c3H5 NH\VR3UxNjFxMD61M|Eh|ryP NUDz[Jp3PDhiaB?= NYq4TngyTE2VTx?= M{HMfolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NFW1VYYzODh6MEGwOy=>
HD-LM2 NWK5XWN3TnWwY4Tpc44hSXO|YYm= NF7zXogyyqEQvF2= M2Xs[VI1NzR6IHi= M13Gc2ROW09? NEW4emdld3ewcnXneYxifGW|IGjJRXAtKGGldHn2ZZRm\CClYYPwZZNmeyB7IHHu[EA{ NED5WmkzODh6MEGwOy=>
L428 MULGeY5kfGmxbjDBd5NigQ>? NHzRdI8yyqEQvF2= M1rLeVI1NzR6IHi= NWfCZ3ZRTE2VTx?= NXPKNYZF\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>? M{jrR|IxQDhyMUC3
KM-H2 NXnUWHQ5TnWwY4Tpc44hSXO|YYm= MUexxsDPxE1? NIjsWnozPC92ODDo MWTEUXNQ M{H5bIRwf26{ZXf1cIF1\XNiWFnBVEwh[WO2aY\heIVlKGOjc4Dhd4V{KDliYX7kJFM> MX6yNFg5ODFyNx?=
HD-LM2 MXLGeY5kfGmxbjDBd5NigQ>? M2P0cVAvPS9zIN88US=> NXizXItTOjRxNEigbC=> MlfOSG1UVw>? NYHSb4FifXC{ZXf1cIF1\XNiVF7GMe6yKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MXyyNFg5ODFyNx?=
L428 NFP3fVlHfW6ldHnvckBCe3OjeR?= MYmwMlUwOSEQvF2= NXvQeY1WOjRxNEigbC=> MmLNSG1UVw>? NFPKdIl2eHKnZ4XsZZRmeyCWTl[t{tEh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MoTSNlA5QDBzMEe=
KM-H2 MUHGeY5kfGmxbjDBd5NigQ>? MXewMlUwOSEQvF2= NIfOVHkzPC92ODDo M2jUNWROW09? NEjkZXl2eHKnZ4XsZZRmeyCWTl[t{tEh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NULoU41kOjB6OECxNFc>
HD-LM2 NWTN[YpRTnWwY4Tpc44hSXO|YYm= M{iyVVHDqM7:TR?= MWmwMlI2NTR6IHi= MYfEUXNQ Mm\IZYN1cX[jdHXzJG5HNWuE MVWyNFg5ODFyNx?=
L428 MYrGeY5kfGmxbjDBd5NigQ>? MnvUNeKh|ryP MmOyNE4zPS12ODDo MXvEUXNQ NGXpOFBi[3SrdnH0[ZMhVkZva1K= NHPnVWozODh6MEGwOy=>
KM-H2 M2f0bGZ2dmO2aX;uJGF{e2G7 NYTyTnpIOcLizszN NYPndG1LOC5{NT20PEBp MULEUXNQ M2njdYFkfGm4YYTld{BPTi2tQh?= Moq2NlA5QDBzMEe=
H526 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPXTWM2OD12OECgcm0> MVqyNFY5OjZ2Mx?=
H146 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7UNZhKSzVyPUO1JI5O NUnFZ|lUOjB4OEK2OFM>
H82 NHTPUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ3MDDuUS=> Mo[wNlA3QDJ4NEO=
DMS114 M1zETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zpRmlEPTB;NkSwJI5O NXjQUY02OjB4OEK2OFM>
HeLa MUfGeY5kfGmxbjDBd5NigQ>? NWK4WpFsOC5|LUGwJO69VQ>? MV24JIg> M2XsUmROW09? NVX5NZN{cW6lcnXhd4V{KGGlZYT5cIF1\WRiSEOgT|khMEh|S{nBZ{kh[XRiMUCg{txO MYSyNFU{QDh2MB?=
HeLa MkPLSpVv[3Srb36gRZN{[Xl? MWCwMlMuOTBizszN M4X4ZlghcA>? NUnqSZpiTE2VTx?= M2PBV4lv[3KnYYPld{Bk[XOyYYPlJFMh[W6mIEegZYN1cX[jdHnvckBld3OnIHTldIVv\GWwdHz5 NUnnV3FQOjB3M{i4OFA>
HeLa M3jNbGZ2dmO2aX;uJGF{e2G7 M1POOVExKM7:TdMg NF7DXGo3NzF{L{K0JIg> MWHEUXNQ MUPpcoR2[2W|IH3peI91cWNiYXPjeY12dGG2aX;uJIFv\CCmZXzhfYVlKHB{MTDlfJBz\XO|aX;u MW[yNFU{QDh2MB?=
HeLa  NIPrd3RHfW6ldHnvckBCe3OjeR?= NXrHbHo{OTBizszNxsA> NGnab2Q4KGh? Mo\GSG1UVw>? NGO1dmdlcXO{dYD0d{Bvd3KvYXygd5BqdmSuZTDjbIVkc3CxaX70JIZ2dmO2aX;u M3[zSFIxPTN6OESw
PBMC  M3y4SWFxd3C2b4Ppd{BCe3OjeR?= Mmn1NE42NzJxMzFOwG0> NU\yepROOjRxNEigbC=> NY[0XHZbcW6mdXPld{BieG:ydH;zbZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MmnQNlA1ODZ7NEe=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Ac-H3 / Ac-H4 / Ac-tubulin ; 

PubMed: 29186204     


Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.

Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; 

PubMed: 27551526     


(a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. 

29186204 27551526
Immunofluorescence
Nanog / MHC ; 

PubMed: 26240433     


c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.

E-cadherin / ZEB1 ; 

PubMed: 25872941     


Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.

26240433 25872941
Growth inhibition assay
Cell viability; 

PubMed: 26378038     


B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software. 

26378038
体内研究 在裸鼠中,MGCD0103明显抑制人类移植瘤的生长,及抑制肿瘤中组蛋白乙酰化诱导的的相关抗癌活性。MGCD0103每天口服处理携带移植的晚期 A549肿瘤 的裸鼠,13天后,明显降低生长,这种作用存在剂量依赖性。MGCD0103与对照组相比,明显阻断肿瘤生长,且体重没有改变。此外, MGCD0103不会使WBC数降低,且耐受性很好。 MGCD0103 作用于许多 其他人类移植瘤模型包括NSCLC H1437,是口服有效的。MGCD0103按80 mg/kg 剂量每天口服给药携带H1437肿瘤的动物,13天后,完全抑制肿瘤生长,且动物体重没有下降。 [1]MGCD0103降低肺动脉高血压症的效果比tadalafil好,tadalafil是治疗肺动脉高血压症的常规法,是一种血管舒张药。此外, MGCD0103提高肺动脉加速时间,且降低肺动脉的收缩,说明HDAC 抑制剂作用于肺血管具有很好效果。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外HDAC酶实验:

根据均相荧光释放法进行脱乙酰化酶活性测定。在实验buffer(包括25 mM HEPES,pH 为8.0, 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl)中,纯化的重组HDAC酶和稀释成不同浓度的MGCD0103一起在室温下温育10分钟。加入底物Boc-Lys(ε-Ac)-AMC,在37oC进一步温育。作用于不同亚型HDAC酶则底物浓度和温育时间都不同。加入胰蛋白酶室温下温育20分钟,脱乙酰化底物释放荧光。在360 , 470, 435 nm 波长处测定荧光信号。
细胞实验:[1]
- 合并
  • Cell lines: 人类乳腺上皮细胞(HMEC)和人类包皮成纤维细胞(MRHF)
  • Concentrations: 0-60 μM
  • Incubation Time: 72小时
  • Method: 人类乳腺上皮细胞(HMEC)和人类包皮成纤维细胞(MRHF)接种在96孔板上,加入不同浓度MGCD0103,在含5% CO2环境37oC下温育72小时。加入3-(4,5-二甲基-2-噻唑基)-2,5-二苯基溴化四唑(MTT),最终浓度为0.5 mg/ml,和细胞一起温育4小时,然后加入同体积溶解buffer,buffer包含50% N,N-二甲基甲酰胺,及20% SDS(pH 为4.7)。温育过夜,在630 nm 处标记,在570 nm 处读数,测量溶解的染料。根据相关细胞系的标准生长曲线计算细胞的吸光值。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带H1437肿瘤的雌性CD-1裸鼠
  • Dosages: 80 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 13 mg/mL (32.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG400+0.5% Tween80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 396.44
化学式

C23H20N6O

CAS号 726169-73-9
储存条件 粉状
溶于溶剂
别名 MG0103

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04299113 Recruiting Drug: Vinorelbine|Drug: Mocetinostat Rhabdomyosarcoma Jonsson Comprehensive Cancer Center|Mirati Therapeutics Inc.|Phase One Foundation May 14 2020 Phase 1
NCT02993991 Withdrawn Drug: Mocetinostat|Biological: Durvalumab Squamous Cell Carcinoma Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral Cavity University Health Network Toronto|Mirati Therapeutics Inc.|AstraZeneca October 10 2017 Phase 1
NCT02805660 Completed Drug: mocetinostat|Drug: durvalumab Advanced Cancer Mirati Therapeutics Inc. May 2016 Phase 1|Phase 2
NCT02236195 Completed Drug: Mocetinostat Urothelial Carcinoma Mirati Therapeutics Inc. October 2014 Phase 2
NCT00666497 Terminated Drug: Azacitidine|Drug: MGCD0103 Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS) Mirati Therapeutics Inc. June 2008 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103)供应商 | 采购Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103)价格 | Mocetinostat (MGCD0103)生产 | 订购Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID